Nal-iri/lv5-fu Versus Paclitaxel as Second Line Therapy in Patients With Metastatic Oesophageal Squamous Cell Carcinoma

Condition:   Squamous Cell Carcinoma
Interventions:   Drug: Onivyde;   Drug: Paclitaxel
Sponsors:   Federation Francophone de Cancerologie Digestive;   Shire
Not yet recruiting

https://ift.tt/2OO0cEF